Search results for "Proto-oncogene"

showing 10 items of 770 documents

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis

2016

Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this metastasis remain poorly understood. To identify key molecules related with pulmonary metastasis of pediatric osteosarcomas, we analyzed high-throughput miRNA expression in a cohort of 11 primary tumors and 15 lung metastases. Results were further validated with an independent cohort of 10 primary tumors and 6 metastases. In parallel, we performed immunohistochemical analysis of activated signaling pathways in 36 primary osteosarcomas. Only phospho-AKT associated with lower overall survival in primary tumors, supporting its role in osteosarcoma progression. CTNNB1 expression a…

0301 basic medicineOncologyMaleCancer ResearchmiR‐200cLung NeoplasmsCDH1MetastasisCohort Studies0302 clinical medicineCell MovementPhospho‐AKTPhosphorylationChildOsteosarcomabiologyGeneral MedicineArticlesCadherinsPrognosisPrimary tumorGene Expression Regulation Neoplasticmedicine.anatomical_structureLung metastasisOncology030220 oncology & carcinogenesisDisease ProgressionMolecular MedicineOsteosarcomaFemaleSignal Transductionmedicine.medical_specialtyAdolescentMesenchymal to epithelial transitionArticle03 medical and health sciencesYoung AdultAntigens CDInternal medicineCell Line TumormicroRNAGeneticsmedicineBiomarkers TumorHumansEpithelial–mesenchymal transitionCell ProliferationLungGene Expression ProfilingReproducibility of ResultsEpithelial CellsPediatric osteosarcomamedicine.diseaseSurvival AnalysisEnzyme ActivationMicroRNAs030104 developmental biologyTumor progressionbiology.proteinProto-Oncogene Proteins c-aktMolecular Oncology
researchProduct

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC

2017

[EN] Background Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathologic features and patient outcome (relapse-free survival, time-to-relapse, overall survival). Methods Clinically annotated, resected stage I¿III NSCLC FFPE tissue was assessed for gene mutation using a microfluidics-based multiplex PCR platform. Mutant-allele detection sensitivity is¿>1% for most of the ~150 (13 genes) mutations covered in the multiplex test.…

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisKRAS MUTATIONSGene mutationmedicine.disease_cause0302 clinical medicinemultiplex mutation analysisCarcinoma Non-Small-Cell LungMultiplex mutation analysisPrevalenceMultiplexAnaplastic Lymphoma KinaseHETEROGENEITYAged 80 and overMutationSmokingHematologyMiddle AgedProto-Oncogene Proteins c-metProgression-Free SurvivalOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleKRASPREDICT SURVIVALAdultmedicine.medical_specialtyEGFRCELL LUNG-CANCERPrognosis molecular stagingprognosis molecular stagingEGFR KRAS PIK3CAVALIDATION03 medical and health sciencesYoung AdultInternal medicineMultiplex polymerase chain reactionmedicineKRASTYROSINE KINASE INHIBITORSHumansProgression-free survivalLung cancerAgedNeoplasm Stagingbusiness.industryMICROBIOLOGIAADENOCARCINOMAAMPLIFICATIONPIK3CAmedicine.disease030104 developmental biologynon-small-cell lung cancerMutationOVEREXPRESSIONbusinessMultiplex Polymerase Chain ReactionNon-small-cell lung cancerAnnals of Oncology
researchProduct

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

2020

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular pre…

0301 basic medicineOncologyProto-Oncogene Proteins B-rafmedicine.medical_specialtyPredictive molecular pathologyLung NeoplasmsGene mutationBRAF03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungMedicineHumansNon-Small-Cell LungVemurafenibLung cancerneoplasmsMelanomaTrametinibCobimetinibbusiness.industryBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathology; Biomarkers; Humans; Mutation; Proto-Oncogene Proteins B-raf; Carcinoma Non-Small-Cell Lung; Lung Neoplasms; MelanomaCarcinomaPrecision medicineDabrafenibHematologyBiomarkerPrecision medicinemedicine.diseaseBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathologyLung Neoplasm030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisMutationPersonalized medicineLung cancerbusinessBiomarkersmedicine.drugHuman
researchProduct

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

2016

Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metast…

0301 basic medicineOncologyendocrine system diseasesColorectal cancerLiver metastasimedicine.medical_treatmentColorectal Neoplasmmedicine.disease_cause0302 clinical medicineLiver metastasisHematologyTumorLiver NeoplasmsHematologyPrognosisSurvival RateOncologyLiver Neoplasm030220 oncology & carcinogenesisMeta-analysisKRASColorectal NeoplasmsHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognostic biomarkerPrognosiResectionBRAFProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicineBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologymedicineKRASBiomarkers TumorHepatectomyHumansneoplasmsSurvival ratebusiness.industrymedicine.diseaseColorectal cancerdigestive system diseasesClinical trial030104 developmental biologyMutationBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers; Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologyHepatectomyGeriatrics and GerontologybusinessBiomarkersCritical reviews in oncology/hematology
researchProduct

Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors

2017

Ewing sarcoma is an aggressive neoplasm of pediatric and adolescent patients. Immunohistochemistry (IHC) can be used to support the morphologic diagnosis of Ewing sarcoma family of tumors (ESFT) in a convincing clinical/radiological context. Although neither NKX2.2 nor CD99 alone are entirely specific, when combined, the diagnostic specificity is high. The aim of the present study was to investigate the IHC expression of NKX2.2, ETV4 and BCOR in a large series of genetically confirmed ESFT. The results for CD99 and CAV-1 immunoreactivity, and the histological and fusion gene subtypes were retrieved from our previous study. NKX2.2 demonstrated moderate or strong nuclear positivity in 91.2% o…

0301 basic medicinePathologymedicine.medical_specialtyCD99Bone NeoplasmsContext (language use)Sarcoma EwingBiologyPathology and Forensic MedicineFusion gene03 medical and health sciences0302 clinical medicineProto-Oncogene ProteinsBiomarkers TumormedicineHumansNeoplasmHomeodomain ProteinsProto-Oncogene Proteins c-etsNuclear ProteinsCell BiologyZebrafish Proteinsmedicine.diseaseImmunohistochemistryRepressor ProteinsHomeobox Protein Nkx-2.2030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinImmunohistochemistryAdenovirus E1A ProteinsSarcomaMorphologic diagnosisAntibodyTranscription FactorsPathology - Research and Practice
researchProduct

Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology

2018

Pulmonary adenocarcinoma with enteric differentiation (PAED) is a rare subtype of lung adenocarcinoma recently recognized in the WHO classification. It is defined as an adenocarcinoma in which the enteric component exceeds 50% and have to show the expression of at least 1 immunohistochemical marker of enteric differentiation. Although the definition of this tumor type is very important, above all in the differential diagnosis between a primary lung tumor and a metastasis of colorectal adenocarcinoma, this cancer still lacks a distinctive immunohistochemical and molecular signature. We recruited the largest series in the literature of PAEDs according to the morphology and the positivity for …

0301 basic medicinePathologymedicine.medical_specialtyLung NeoplasmsHistologyintestinal-type adenocarcinomaCellular differentiationDNA Mutational AnalysisThyroid Nuclear Factor 1AdenocarcinomaBiologymedicine.disease_causePathology and Forensic MedicineMetastasisDiagnosis DifferentialProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineKRASBiomarkers TumormedicineHumansCDX2 Transcription FactorPathology Molecularenteric lung adenocarcinoma intestinal-type adenocarcinoma CDX-2 CDX2 KRASLungKeratin-7entericCancerCell DifferentiationPulmonary adenocarcinoma with enteric differentiation (PAED)lung adenocarcinomamedicine.diseaseCDX-2ImmunohistochemistryMedical Laboratory Technology030104 developmental biologymedicine.anatomical_structureCDX2Alveolar Epithelial Cells030220 oncology & carcinogenesisMutationAdenocarcinomaImmunohistochemistryKRASDifferential diagnosisColorectal Neoplasms
researchProduct

Estrogen Receptor Signaling and the PI3K/Akt Pathway Are Involved in Betulinic Acid-Induced eNOS Activation

2016

Betulinic acid (BA) is a naturally occurring pentacyclic triterpenoid with anti-inflammatory, antiviral and anti-cancer properties. Beneficial cardiovascular effects such as increased nitric oxide (NO) production through enhancement of endothelial NO synthase (eNOS) activity and upregulation of eNOS expression have been demonstrated for this compound. In the present study, immortalized human EA.hy 926 endothelial cells were incubated for up to 1 h with 1–100 µM BA and with the phosphatidylinositol-3-kinase (PI3K) inhibitors LY294002 and wortmannin, or the estrogen receptor (ER) antagonist ICI 182,780. Phosphorylation status of eNOS and total eNOS protein were analyzed by Western blotting us…

0301 basic medicinePharmaceutical ScienceEstrogen receptorPI3KAnalytical ChemistryWortmanninchemistry.chemical_compound0302 clinical medicineEnosDrug DiscoveryLY294002PhosphorylationFulvestrantLungbiologyEstradiolendothelial cellsReceptors EstrogenChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicinePhosphorylationSignal transductionPentacyclic TriterpenesWortmanninSignal Transductionestrogen receptormedicine.medical_specialtyNitric Oxide Synthase Type IIIMorpholinesArticleCell Linelcsh:QD241-44103 medical and health sciencesbetulinic acidlcsh:Organic chemistryInternal medicinemedicineAnimalsHumansPhysical and Theoretical ChemistryProtein kinase BPI3K/AKT/mTOR pathwayendothelial nitric oxide synthaseAktOrganic ChemistryFibroblastsbiology.organism_classificationMolecular biologyTriterpenesbetulinic acid; endothelial nitric oxide synthase; endothelial cells; estrogen receptor; PI3K; AktRatsAndrostadienes030104 developmental biologyEndocrinologychemistryGene Expression RegulationChromonesPhosphatidylinositol 3-KinaseProto-Oncogene Proteins c-aktMolecules
researchProduct

Target Identification of Active Constituents of Shen Qi Wan to Treat Kidney Yang Deficiency Using Computational Target Fishing and Network Pharmacolo…

2019

Background: Kidney yang deficiency syndrome (KYDS) is one of the most common syndromes treated with traditional Chinese medicine (TCM) among elderly patients. Shen Qi Wan (SQW) has been effectively used in treating various diseases associated with KYDS for hundreds of years. However, due to the complex composition of SQW, the mechanism of action remains unknown. Purpose: To identify the mechanism of the SQW in the treatment of KYDS and determine the molecular targets of SQW. Methods: The potential targets of active ingredients in SQW were predicted using PharmMapper. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were carried out using the …

0301 basic medicinePharmacology03 medical and health scienceschemistry.chemical_compoundtraditional Chinese medicinetranscriptomics0302 clinical medicinemedicinenetwork pharmacologyPharmacology (medical)HRASKEGGBlood urea nitrogenMAPK14Original ResearchPharmacologyCreatinineKidneylcsh:RM1-950phytotherapy030104 developmental biologymedicine.anatomical_structurelcsh:Therapeutics. PharmacologychemistryMechanism of action030220 oncology & carcinogenesisgene ontologypotential targetsmedicine.symptomProto-oncogene tyrosine-protein kinase SrcFrontiers in Pharmacology
researchProduct

Curcumin at Low Doses Potentiates and at High Doses Inhibits ABT-737-Induced Platelet Apoptosis

2021

Curcumin is a natural bioactive component derived from the turmeric plant Curcuma longa, which exhibits a range of beneficial activities on human cells. Previously, an inhibitory effect of curcumin on platelets was demonstrated. However, it is unknown whether this inhibitory effect is due to platelet apoptosis or procoagulant platelet formation. In this study, curcumin did not activate caspase 3-dependent apoptosis of human platelets, but rather induced the formation of procoagulant platelets. Interestingly, curcumin at low concentration (5 µM) potentiated, and at high concentration (50 µM) inhibited ABT-737-induced platelet apoptosis, which was accompanied by inhibition of ABT-737-mediated…

0301 basic medicinePharmacologyPiperazinesNitrophenolschemistry.chemical_compound0302 clinical medicinePlateletBiology (General)SpectroscopyCaspaseSulfonamidesbiologyKinaseapoptosisGeneral MedicinethrombinDrug Resistance Multipleprocoagulant activityComputer Science ApplicationsChemistry030220 oncology & carcinogenesisplateletsmedicine.drugBlood PlateletsAdenosine monophosphateautophagyCurcuminQH301-705.5ArticleCatalysisInorganic Chemistry03 medical and health sciencesCurcumaThrombinmedicineHumansATP Binding Cassette Transporter Subfamily B Member 1Physical and Theoretical ChemistryQD1-999Molecular BiologyProtein kinase BPlant ExtractsBiphenyl CompoundsOrganic ChemistryAdenosine Monophosphate030104 developmental biologychemistryApoptosisbiology.proteinCurcuminProto-Oncogene Proteins c-aktPlatelet Aggregation InhibitorsInternational Journal of Molecular Sciences
researchProduct

Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity.

2020

The memory CD8 T-cell pool must select for clones that bind immunodominant epitopes with high affinity to efficiently counter reinfection. At the same time, it must retain a level of clonal diversity to allow recognition of pathogens with mutated epitopes. How the level of diversity within the memory pool is controlled is unclear, especially in the context of a selective drive for antigen affinity. We find that preservation of clones that bind the activating antigen with low affinity depends on expression of the transcription factor Eomes in the first days after antigen encounter. Eomes is induced at low activating signal strength and directly drives transcription of the prosurvival protein…

0301 basic medicinePhysiologyAntigenic Variation/immunologyApoptosisCD8 memory viral infection Eomesddc:616.07CD8-Positive T-LymphocytesLymphocyte ActivationEpitopeMemory T cellsMice0302 clinical medicineSpectrum Analysis TechniquesCognitionLearning and MemoryTranscription (biology)Immune PhysiologyReceptorsCellular typesCytotoxic T cellBiology (General)ReceptorClonal Selection Antigen-MediatedCell Survival/immunologyT-Cell/genetics/immunologyT-Lymphoid/immunologyCells CulturedFluorescence-Activated Cell SortingCulturedGeneral NeuroscienceImmune cellsFlow CytometryAntigenic VariationCell biologyProto-Oncogene Proteins c-bcl-2SpectrophotometryAntigenWhite blood cellsT-Box Domain Proteins/genetics/immunologyCytophotometrySignal transductionBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.General Agricultural and Biological SciencesApoptosis/immunologySignal TransductionResearch ArticleCell biologyBlood cellsQH301-705.5Precursor CellsCell SurvivalCellsImmunologyClonal SelectionReceptors Antigen T-CellT cellsCytotoxic T cellsBiologyCD8-Positive T-Lymphocytes/immunologyResearch and Analysis MethodsGeneral Biochemistry Genetics and Molecular BiologyAntigen-Mediated/genetics/immunology03 medical and health sciencesAntigenMemoryAnimalsMolecular Biology TechniquesTranscription factorMolecular BiologyMedicine and health sciencesPrecursor Cells T-LymphoidGene Expression Regulation/immunologyGeneral Immunology and MicrobiologyBiology and life sciencesBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.T-cell receptorProto-Oncogene Proteins c-bcl-2/genetics/immunology030104 developmental biologyGene Expression RegulationAnimal cellsCognitive ScienceT-Box Domain ProteinsImmunologic Memory030217 neurology & neurosurgerySpleenCloningNeurosciencePLoS biology
researchProduct